The Annual Congress on Anti-Aging Medicine and Regenerative Biomedical Technologies 2010

Prof. Peskin is co-chairman of Cardiology with The Academy of Anti-again medicine. On Tuesday, December 10, he will lecture on `The Failure of Vytorin and Statins` in Las Vegas, Nevada.

The clinical failure of Vytorin in the ENHANCE trial supports the need to reevaluate the efficacy of widespread use of statin drugs for the treatment and prevention of coronary artery disease (CAD). Statins were marketed on the precept that lowering so-called bad cholesterol while raising good cholesterol significantly improves cardiovascular outcomes. The number needed to treat (NNT) is, however, often greater than 100 (99% failure rate) with statin use. Examination of the biochemical and physiological nature of atherosclerotic plaques suggests a reason for statin failure. Plaques rupture because of oxidized linoleic acid (LA), the parent omega-6 essential fatty acid, and while statins hinder transport of nonfunctional LA (trans and oxidized) entities to the intima, they also lower the bioavailability of fully functional LA. This lower bioavailability promotes platelet adhesion, lowers the antiinflammatory levels of key prostaglandins, and interferes with cell membrane fluidity and oxygen transmission. Moreover, pharmacologically raising high-density lipoprotein cholesterol (HDL-C) good cholesterol levels is strongly associated with adverse cardiovascular events. An exciting solution obtaining `remarkable` hard plaque reversal results even in smokers (MDCT 64-slice scan data) is given.

Goals 1. Explain a significantly better solution to preventing and reversing CVD as verified by recent MDCT scans.

1. Explain physiologically why lowering LDL cholesterol is not `the answer` to preventing CVD.
   
   
2. Explain what `number needed to treat` (NNT) means and why statin`s high NNT by the pharmaceutical industry means they are not successful in preventing or treating CVD.
   
   

Bio Brian Peskin earned his Bachelor of Science degree in Electrical Engineering from Massachusetts Institute of Technology (M.I.T.) in 1979. He received an appointment as an Adjunct Professor at Texas Southern University in the Department of Pharmacy and Health Sciences (1998-1999). The former president of the University said of Brian`s discoveries: `...His nutritional discoveries and practical applications through Life-Systems Engineering are unprecedented.` His focus is on the cancer/oxygen connection and its ramifications. Brian founded the field of Life-Systems Engineering Science in 1995. This field is defined as The New Science of Maximizing Desired Results by Working Cooperatively with the Natural Processes of Living Systems.